In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted ...
Constitutive activation of the B-cell receptor (BCR) signaling pathway is a hallmark of chronic lymphocytic leukemia (CLL), driving the malignant cell survival, proliferation, and interaction with the ...
Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results